Research Supported by Bay Area Lyme Foundation Evaluates Anti-microbial Effects of 14 Natural Products Compared to Antibiotics Used to Treat Lyme Disease
MARIN, Calif., Feb. 21, 2020 /PRNewswire/ -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data finding that seven herbal medicines are highly active in test tubes against B. burgdorferi, the bacteria that causes Lyme disease, compared to the control antibiotics, doxycycline and cefuroxime. Published in the journal Frontiers in Medicine, the laboratory study was funded by Bay Area Lyme Foundation and supported in part by the Steven & Alexandra Cohen Foundation. The study was a collaboration between researchers at Johns Hopkins Bloomberg School of Public Health and colleagues at the California Center for Functional Medicine and FOCUS Health Group, Naturopathic.
"Since traditional antibiotic approaches fail to resolve symptoms in up to 25% of patients treated for Lyme disease and many suffer disabling effects of the disease, there is a need for novel treatment proven effective against B. burgdorferi," said the paper's co-author Sunjya K. Schweig, MD, CEO and co-director, California Center for Functional Medicine and Scientific Advisory Board Member, Bay Area Lyme Foundation. "Because patients are currently turning to herbal remedies to fill the treatment gaps left by antibiotics, this research is a critical step in helping clinicians, as well as patients, understand which ones may offer the most potential benefit."
According to this laboratory study, carried out by Prof. Ying Zhang's group at the Johns Hopkins Bloomberg School of Public Health, the seven herbal medicines that have the ability to kill B. burgdorferi in test tubes are:
Juglans nigra (Black walnut)
Polygonum cuspidatum (Japanese knotweed)
Artemisia annua (Sweet wormwood)
Uncaria tomentosa (Cat's claw)
Scutellaria baicalensis (Chinese skullcap)
It is important to note that each of these products have the potential to produce significant side effects in patients, and should be taken only under advisement of a clinician knowledgeable of their capabilities and toxicities.
Of these products, the Cryptolepis sanguinolenta extract caused complete eradication, while doxycycline and cefuroxime and other active herbs did not. This extract has been used for the treatment of malaria as well as the tick-borne infection Babesia, a malaria-like parasite. This study is believed to be the first time this extract has been documented to have a potential impact on B. burgdorferi, and additional laboratory and clincial studies should be conducted to investigate the potential role Cryptolepis sanguinolenta could play in the treatment of Lyme disease.
Further, Cryptolepis sanguinolenta and Polygonum cuspidatum (Japanese knotweed) showed strong activity against both growing B. burgdorferi (MIC=0.03%-0.06% and 0.25%-0.5% respectively) and non-growing stationary phase B. burgdorferi.
In contrast, Stevia rebaudiana, Andrographis paniculata, Grapefruit seed extract, colloidal silver, monolaurin, and antimicrobial peptide LL37 had little or no activity against stationary phase B. burgdorferi.
"Our hope is that findings from this study could point to new therapeutic options for doctors and their patients, and pave the way for clinical research to help patients with persistent Lyme disease," said Linda Giampa, executive director, Bay Area Lyme Foundation.
These data may provide a basis for the clinical improvement of patients who take herbal medicines, particularly those whose chronic symptoms may be due to persistent bacteria that are not killed by conventional Lyme antibiotic treatment. However, it is critical to note that additional studies are needed to further evaluate the seven active botanical medicines identified in the study. Patients should not attempt to self-treat with these herbal medicines due to potential side effects and lack of clinical trials with these products.
About the Study
For the study, the researchers tested 14 natural products in test tubes against B. burgdorferi. Plant extracts selected for the study included herbs or agents that: have been previously used to manage the symptoms of patients who do not respond to standard Lyme antibiotic treatment; have favorable safety profiles; and can be absorbed systemically. Additional criteria for selecting compounds included anti-biofilm effects and ability to cross the blood-brain barrier. To conduct the study, the plant extracts in concentrations of 1%, 0.5% and 0.25% and antibiotic controls were each tested on growing as well as non-growing B. burgdorferi cultures. The study found that seven of these natural product extracts at 0.25%-0.5% had better activity against the stationary phase B. burgdorferi culture than the control antibiotics doxycycline and cefuroxime, both of which are commonly used to treat Lyme disease.
The paper titled "Evaluation of Natural and Botanical Medicines for Activity against Growing and Non-growing Forms of B. burgdorferi," was written by Jie Feng, PhD, Jacob Leone, ND, Sunjya Schweig, MD, and Ying Zhang, MD, PhD.
About Lyme Disease
The most common vector-borne infectious disease in the country, Lyme disease is a potentially disabling infection caused by bacteria transmitted through the bite of an infected tick to people and pets. If caught early, most cases of Lyme disease can be effectively treated, but it is commonly misdiagnosed due to lack of awareness and unreliable diagnostic tests. There are more than 400,000 new cases of Lyme disease each year, according to statistics released in 2018 by the CDC. As a result of the difficulty in diagnosing and treating Lyme disease, at least two million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates.
About the Cohen Lyme & Tickborne Disease Initiative
The non-profit organization, the Steven & Alexandra Cohen Foundation, is leading the fight against Lyme and tickborne diseases by educating health professionals, sharing new knowledge, advancing research, accelerating market solutions, and advocating the highest quality care for patients. It advances academic science, creates educational tools and platforms, communicates the latest information and study findings, supports policies that promote the highest quality patient care, strengthens the pipeline of tickborne disease specialists and other health professionals, and focuses on addressing health disparities. The Foundation also collaborates with the U.S. government as well as patient, health, and science professionals and other organizations to advance mutually shared goals, including greater awareness of Lyme and tickborne diseases. To learn more, please visit steveandalex.org.
About Bay Area Lyme Foundation
Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is a leading public not-for-profit sponsor of innovative Lyme disease research in the U.S. A 501c3 non-profit organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. A pivotal donation from The LaureL STEM Fund covers overhead costs and allows for 100% of all donor contributions to Bay Area Lyme Foundation to go directly to research and prevention programs. For more information about Lyme disease or to get involved, visit www.bayarealyme.org or call us at 650-530-2439.
SOURCE Bay Area Lyme Foundation